CTLA4 and colitis: This symptom is often associated with colitis, another common irAE, as it is reported in 16% (vs. 11% for grade 3-4) (combination of CTLA-4 and PD-(L)1 inhibitors), 8% (vs. 5% for grade 3-4) (anti-CTLA-4), and 1% (vs. 1% for grade 3-4) (anti-PD-(L)1) of ICI-treated patients (34).